CANSD - Willow Bioscience Announces 3 Million dollar Fundraising to Support Partnership with Laurus Labs

(NewsDirect)

Willow Bioscience CEO Dr Chris Savilejoined Steve Darling from Proactive to share the company's plansto raise approximately $3 million. This capital will be used tosupport Willow Bioscience's recent partnership announcement withLaurus Labs.

Dr. Savile explainedthat the deal with Laurus is a multi-product development and licensingpartnership with a leading research-driven pharmaceutical andbiotechnology company. Laurus Labs, with a market cap of $3.9 billion,serves global pharmaceutical companies and offers Contract Developmentand Manufacturing Organization (CDMO) services. Since its inception,Laurus has commercialized over 80 products and operates ninemanufacturing facilities, including those with fermentationcapabilities.

Willow Bioscience aimsto leverage its AI-driven technology platform and extensive expertisein enzyme, strain, and process engineering to develop biobasedprocesses for high-value Active Pharmaceutical Ingredients (APIs).This includes Willow’s BioOxi™-based corticosteroid processes,intended for large-scale manufacturing, sales, and distribution atLaurus Labs. The first programs from this partnership are expected toreach commercial manufacturing by 2025.

The planned fundraising will provide the necessary capital toadvance these initiatives, ensuring that Willow Bioscience caneffectively collaborate with Laurus Labs to bring innovative biobasedpharmaceutical solutions to the market.

ContactDetails

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2024 TheNewswire - All rights reserved.